D3 Bio Secures Major Funding for Clinical Innovations
D3 Bio, a pioneering global clinical-stage biotechnology firm, recently announced the successful completion of a significant $108 million Series B financing round. This funding marks a pivotal moment for the company, solidifying its commitment to the discovery and advancement of cutting-edge oncology therapeutics.
Investor Confidence Shines Through
The Series B financing attracted a host of esteemed investors, including IDG Capital and SongQing Capital, alongside contributions from existing supporters such as WuXi AppTec's Corporate Venture Fund, Temasek, HSG, MPCi, and Medicxi. This robust backing reflects a strong faith in D3 Bio's comprehensive pipeline and strategic plans for global development.
Funding Impact on Clinical Trials
Proceeds from this substantial financing will primarily propel the company’s lead asset, elisrasib (D3S-001), into a global Phase III pivotal program. These crucial trials are designed to evaluate elisrasib both as a standalone therapy and in combination with other treatments for patients with KRAS G12C-mutant cancers. D3 Bio aims to conduct these studies across critical markets to support submissions for regulatory approval worldwide.
Advancing Pipeline with Innovative Therapies
In addition to funding late-stage clinical trials, this financial boost will facilitate the ongoing development of D3 Bio's extensive pipeline that focuses on targeted and immuno-oncology programs. The company’s innovative approach is centered on exploiting unique mechanisms that may offer first-in-class or best-in-class solutions for patients.
Leadership Vision
Dr. George Chen, Founder, Chairman, and CEO of D3 Bio, highlighted the implications of this financing: "The quantitative completion of our Series B funding indicates our investors' faith in our strategic vision, scientific methodology, and operational capabilities worldwide. This financial infusion empowers us to push our lead program into advanced clinical trials while enriching our lineup of innovative therapies that cater to patients globally."
Scientific Validation of Innovation
Board member Dr. Antoine Yver emphasized the significance of this funding, stating, "This successful financing round illustrates how swiftly pursuing first- or best-in-class science can profoundly impact society. It substantiates D3 Bio's role as a leader in oncology innovation and outlines the substantial potential of elisrasib for patients with KRAS G12C-mutant cancers."
About D3 Bio
D3 Bio is committed to revolutionizing the field of biotechnology through its focus on oncology and immunology. The organization employs proprietary clinical insights and biomarker strategies to pioneer new medications. Its dedicated oncology programs target critical mutations and immune pathways, showcasing the ambition to create therapies with first-in-class or best-in-class capabilities. Through its rigorous approach, D3 Bio maintains global rights for all its programs, ensuring a pathway to success in medical advancements.
Frequently Asked Questions
What is the amount raised in D3 Bio's Series B financing?
D3 Bio successfully raised $108 million in its Series B financing round.
Who are some of the notable investors in this funding round?
Investors include IDG Capital, SongQing Capital, WuXi AppTec’s Corporate Venture Fund, Temasek, and others.
What will the funding primarily support?
The funding will primarily support the global Phase III clinical trials for D3 Bio's lead asset, elisrasib (D3S-001).
What is the focus of D3 Bio?
D3 Bio focuses on the discovery, development, and registration of new medicines in oncology and immunology, emphasizing innovative therapies.
What is elisrasib targeting?
Elisrasib primarily targets KRAS G12C-mutant cancers, assessing its efficacy both as a monotherapy and in combination therapies.
